Author Archives: Marc Whitehead

Risperdal Legal Recourse: The Johnson and Johnson Study

Published on August 28, 2015 by Marc Whitehead

By 2003, multiple research studies indicating that Risperdal might be dangerous for patients, especially children, began drawing negative attention to Janssen and its marketing practices. In response, parent company Johnson & Johnson published a paper entitled "Prolactin levels during long-term Risperidone treatment in children and adolescents." The paper stated ...

Published in Risperdal

Viagra and Melanoma: Is Pfizer Responsible?

Published on August 26, 2015 by Marc Whitehead

As a pharmaceutical company, Pfizer has a responsibility to perform adequate research on all of the drugs it sells to the public. These studies should explore the safety of the drug, the side effects it causes and its effectiveness in treating the conditions it has been manufactured to address. ...

Published in Viagra

Risperdal Legal Recourse: How was Risperdal Marketed to Children?

Published on August 21, 2015 by Marc Whitehead

In our previous post we explored the history of the Risperdal’s development by the pharmaceutical company Janssen. Now let’s talk about how Janssen marketed Xarelto to children and adolescents without thoroughly testing the drug on this age group.

Although the drug was initially marketed to adults, Janssen has ...

Published in Risperdal